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Introduction: The 17α-hydroxyprogesterone (17OHP) mea-
surement is useful to confirm the diagnosis of congenital adrenal 
hyperplasia (CAH) in neonates and nonclassical forms of CAH in 
symptomatic children. During the first year of life, methods may 
be affected by interfering steroids produced by the fetal zone of the 
adrenal gland. This zone produces high concentrations of 17-hy-
droxypregnenolone sulphate carrying immunoreactive epitopes 
similar to the 17OHP molecule. Numerous authors agree that 
these interferences could be removed efficiently via a solvent or-
ganic extraction before measuring the 17OHP. Since the degree of 
interference may vary among different commercially available as-
says, reference intervals (RI) for 17OHP should be method spe-
cific, especially during the first year of life.
The aim of our study was to verify the specified RI for the ELI-
SA method, and correlate this with values obtained after organic 
solvent extraction in infants during the first year of life.
Materials and methods: Serum 17OHP was measure via ELI-
SA method (DRG) in 217 infants aged <1 year classified in 4 
groups: I (0-30 days), II (31-60 days), III (61-180 days) and IV 
(181-360 days), who attended the hospital between Dec 2014 and 
Jul 2019, before (17OHP NE) and after (17OHP E) modified ex-
traction procedure (Makela et al.)
Results: A significant difference between NE and E results was 
observed for all groups (p<0,001), especially during the first two 
month of life. 93.0, 60.5, 90.9 and 90.4% of patients were inside RI 
proposed by the manufacturer for groups I, II, III and IV respec-
tively. Regression values in each groups E and NE were low 
(r2<0.36), demonstrating high interference variability in the same 
group. The serum concentration was log-transformed to reach 
normal distribution. We used one-way ANOVA showing signifi-
cant differences between groups. Tukey post hoc could differenti-
ate all groups, except I and II.
Conclusions: According to the CLSI Evaluator Protocol (EP) 
C28-A3, a result is satisfactory for validation of RI when more than 
90% of the results are inside the range proposed by the manufac-
turer. In our study group II couldn´t be validated, but it is similar 
to group I, so we should establish our own RI for this population. 
As was previously showed for RIA methods, solvent extraction 
procedure is also required in the ELISA DRG method to minimize 
cross-reaction with interfering steroids during the first year of life.
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Background: CNS tumors are the most frequent solid tumors 
in children. In paediatric gliomas, IGF-1R nuclear localization was 
associated with high grade tumours and increased risk of death, 
contributing to the aggressive phenotype of glioblastoma. For chil-
dren chemotherapy after surgical resection is the mainstay of ther-
apy. However, the best regimen needs to be determined.
Aim: To characterize the response of glioblastoma cells to treat-
ment with OSI906 (IGF1R/IR dual inhibitor) alone or in combina-
tion with Temozolomide used as a current adjuvant chemotherapy 
for paediatric patients.
Methods: stably transfected U87Mg glioblastoma cells with 5 
times basal expression of wild type mature GFP-IGF1R fusion pro-
tein (wt-IGF1R, WtU87) or GFP-IGF1R fusion protein mutated in 
Lys1025-1100-1120 to avoid IGF-1R nuclear translocation (m-IG-
F1R, MutU87) were used for in vitro and in vivo assays. Prolifera-
tion assays were carried out for 3 days using complete media 
(10%FBS) alone or with the addition of IGF-1R/IR inhibitor 
OSI906 (0.5uM), Temozolomide (TMZ, 40 or 100uM) or the com-
bination of both. Male nude mice were injected with 1,5e6cells/
flank/mice. OSI906 (50mg/kg) and TMZ (400mg/kg) were given 
by gavage once daily or as a single dose respectively. Treatments 
were started when tumors reached 150 mm3.
Results: After 24 h of culture, MutU87 cells showed decreased 
proliferation when treated with TMZ40 and OSI906; OSI906 had 
an additive effect when combined with TMZ40 compared to con-
trol condition. However, cells resumed proliferation after 3 days in 
culture. On the contrary, treatment with TMZ100 had a strong 
inhibitory effect, that was not increased by the combination with 
OSI906. WtU87 treated with TMZ40 or 100 also resumed prolif-
eration after 24 h treatment, although the total number of cells was 
decreased compared to control. OSI906 was able to abolish prolif-
eration of WtU87 cells when used alone or in combination with 
TMZ 40 or 100, having the latter the strongest effect. In vivo stud-
ies showed similar trends.
Conclusion: The capacity of the IGF1R to translocate to the 
nucleus, renders glioblastoma cells sensitive to the IGF-1R target-
ed therapy alone or in combination with TMZ, in vitro and in vivo. 
These results suggest that the use of IGF1R inhibitors in pediatric 
patients showing nuclear localization for this receptor, could be 
useful to reduce TMZ doses and or avoid radiotherapy in children.
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